Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 18/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986893 | 1.00 | SLC5A2 (0.50) | SLC5A2HTR2AHTR2CHTR2B | |
| SCHEMBL4987870 | 1.00 | SLC5A2 (0.50) | SLC5A2HTR2AHTR2CHTR2B | |
| SCHEMBL4087278 | 1.00 | SLC5A2 (0.50) | SLC5A2HTR2AHTR2CHTR2B | |
| SCHEMBL15284838 | 0.86 | SLC5A2 (0.68) | SLC5A2 | |
| SCHEMBL4081713 | 0.82 | SLC5A2 (0.36) | SLC5A2 | |
| SCHEMBL4718151 | 0.82 | SLC5A2 (0.36) | SLC5A2 | |
| SCHEMBL13245435 | 0.79 | SLC5A2 (0.47) | SLC5A2HTR2AHTR2CHTR2B | |
| SCHEMBL4077235 | 0.79 | EPHX1 (0.43) | SLC5A2 | |
| SCHEMBL19329994 | 0.79 | EPHX1 (0.43) | SLC5A2 | |
| SCHEMBL4086552 | 0.79 | EPHX1 (0.43) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410996-B2 | 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-20080146645-A1 | Process for Preparing Indolinone Phenylaminopropanol Derivatives | WYETH (US) | 2008-06-19 | — | — | US | disclosed |
| EP-1931631-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth a Corporation of the State of Delaware (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008024492-A2 | INDOLINONE PHENYLAMINOPROPANOL DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | WYETH (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007041023-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20060173035-A1 | 3-Aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ELI LILLY AND COMPANY (US) | 2006-08-03 | — | — | US | disclosed |
| EP-1587781-A1 | 3-ARYLOXY/THIO-2,3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE | ELI LILLY AND COMPANY (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004043903-A1 | 3-ARYLOXY/ THIO-2, 3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE | ELI LILLY AND COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146645-A1 | Process for Preparing Indolinone Phenylaminopropanol Derivatives | IDO1, CYP1A1, IDO2 | SLC5A2 4261/4885HTR2A 93/4885HTR2C 123/4885 |
| US-20060173035-A1 | 3-Aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake | ADRB3, SLC6A3, SLC6A2 | SLC5A2 412/4885HTR2A 142/4885HTR2C 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.